Updated:
AtriCure
AtriCure develops surgical ablation devices for atrial fibrillation, including the AtriClip and cryoablation probes.
AtriCure
AtriCure provides innovative atrial fibrillation (Afib) treatment solutions, including the AtriClip device for LAAM and other surgical ablation therapies.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
West Chester
Corporate office
West Chester, United States
Sector focus
Frequently asked questions
Does AtriCure operate as a family office or investment firm?
No. AtriCure is a publicly-traded medical device company (NASDAQ: ATRC) focused on surgical treatment of atrial fibrillation. It does not manage capital for external investors or function as a family office.
What products does AtriCure sell?
AtriCure's main products include the AtriClip device line for left atrial appendage management, cryoablation probes (cryoFORM, cryoICE, cryoXT), and the EPi-Sense system for hybrid AF therapy. The company also offers the ORLab system and various surgical instruments.
Who are AtriCure's customers?
AtriCure sells directly to hospitals and cardiothoracic surgeons in the United States and internationally. Its devices are used in concomitant cardiac surgery, hybrid AF procedures, and cryo nerve block.
How does AtriCure invest its capital?
AtriCure invests internally in R&D, clinical trials, manufacturing, and commercial expansion. It does not deploy capital into external companies, funds, or securities.
Is AtriCure profitable?
AtriCure's financial performance is disclosed in its SEC filings. As a public company, it reports quarterly revenue, operating expenses, and net income. Recent profitability status should be verified from its 10-K or 10-Q.
Where is AtriCure headquartered?
AtriCure is headquartered in West Chester, Ohio, United States. It operates additional facilities but does not disclose full office locations on its website.
What regulatory approvals does AtriCure hold?
AtriCure's devices are regulated by the FDA in the United States and by equivalent agencies in other countries. Many products carry CE marking for European distribution. Specific approvals vary by product and market.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: